Amneal Pharmaceuticals, Inc. (AMRX) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
AMRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AMRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 36.9% | -0.2% | 2.4% |
| 2024 | 36.5% | 8.9% | -4.2% |
| 2023 | 36.1% | 8.5% | -3.5% |
| 2022 | 35.8% | -4.3% | -5.9% |
| 2021 | 36.7% | 7.3% | 0.5% |
Download Data
Export AMRX earnings history in CSV or JSON format
Free sign-in required to download data
Amneal Pharmaceuticals, Inc. (AMRX) Earnings Overview
As of May 8, 2026, Amneal Pharmaceuticals, Inc. (AMRX) reported trailing twelve-month net income of $72M, reflecting +157.9% year-over-year growth. The company earned $0.22 per diluted share over the past four quarters, with a net profit margin of 2.4%.
Looking at the long-term picture, AMRX's 5-year EPS compound annual growth rate (CAGR) stands at -18.5%, signaling declining earnings. The company achieved its highest annual net income of $207M in fiscal 2016.
Amneal Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 36.9%, operating margin of -0.2%, and net margin of 2.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including TEVA ($1.56B net income, 8.2% margin), VTRS (-$296M net income, -24.6% margin), PRGO (-$1.82B net income, -33.5% margin), AMRX has room to improve margins relative to the peer group. Compare AMRX vs TEVA →
AMRX Earnings vs Peers
Earnings metrics vs comparable public companies
AMRX Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $72M | +161.6% | -$5M | $0.22 | 2.4% | -0.2% |
| 2024 | -$117M | -39.2% | $249M | $-0.38 | -4.2% | 8.9% |
| 2023 | -$84M | +35.4% | $204M | $-0.48 | -3.5% | 8.5% |
| 2022 | -$130M | -1323.5% | -$95M | $-0.86 | -5.9% | -4.3% |
| 2021 | $11M | -88.3% | $153M | $0.07 | 0.5% | 7.3% |
| 2020 | $91M | +125.2% | $91M | $0.61 | 4.6% | 4.6% |
| 2019 | -$362M | -113.2% | -$249M | $-4.57 | -22.3% | -15.3% |
| 2018 | -$170M | -201.2% | -$20M | $-1.33 | -10.2% | -1.2% |
| 2017 | $168M | -19.2% | $245M | $1.46 | 16.2% | 23.7% |
| 2016 | $207M | +22.4% | $285M | $1.10 | 20.4% | 28.0% |
See AMRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAMRX — Frequently Asked Questions
Quick answers to the most common questions about buying AMRX stock.
Is AMRX growing earnings?
AMRX EPS is $0.22, with earnings growth accelerating to +157.9%. This exceeds the 5-year CAGR of -18.5%. TTM net income reached $72M.
What are AMRX's profit margins?
Amneal Pharmaceuticals, Inc. net margin is +2.4%, with operating margin at -0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are AMRX's earnings?
AMRX earnings data spans 2015-2025. The accelerating earnings trend is +157.9% YoY. Historical data enables comparison across business cycles.